Stockreport

Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes

Tempus AI, Inc. - Class A  (TEM) 
PDF New study published in Nature Communications builds on Ambry’s contributions to MAVE research to deepen understanding of PALB2 and its role in hereditary cancer predispo [Read more]